149357-93-7Relevant academic research and scientific papers
Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors
Chan, Grace Ka Yan,Chen, Huifen,Chen, Yong,Dimitrova, Yoana N.,Hu, Dennis X.,Huang, Haochu,Lee, Joanna Y.,Lim, Junghyun,McNamara, Erin,Moffat, John G.,Murthy, Aditya,Pang, Jodie,Patel, Snahel,Prangley, Madeleine S.,Salphati, Laurent,Schutt, Leah K.,Siu, Michael,Sneeringer, Christopher J.,Staben, Steven T.,Wallweber, Heidi Ackerly,Wang, Shumei,Wang, Yunli,Wu, Kai C.,Zhao, Wensheng
supporting information, (2021/12/02)
VPS34 is a class III phosphoinositide 3-kinase involved in endosomal trafficking and autophagosome formation. Inhibitors of VPS34 were believed to have value as anticancer agents, but genetic and pharmacological data suggest that sustained inhibition of V
Retroviral protease inhibitors
-
, (2008/06/13)
The present invention provides compounds, more particularly dipeptide analogs, which bind to retroviral proteases. These compounds are inhibitors of retroviral proteases and are useful for treating diseases related to infection by retroviruses.
